Cancer Immunotherapy Guidelines Renal Cell Carcinoma

The first evidence-based consensus statement on tumor immunotherapy for the treatment of patients with renal cell carcinoma was developed by the Society for Immunotherapy of Cancer (SITC) and published online by the Journal for ImmunoTherapy of Cancer, in 2016.

This consensus statement provides expert evidence-based recommendations for the use of cytokine-based immunotherapies, IL-2 and IFN, and the more recently approved drug, nivolumab, a checkpoint inhibitor. This statement includes recommendations for patient selection, toxicity management, clinical end points, and sequencing or combination of therapies.

Current Guideline

update in progress

Published Nov. 15, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma."

Pocket Guides

Key points from SITC's Cancer Immunotherapy Guidelines Renal Cell Carcinoma have been distilled into Pocket Guide. This condensed, easily accessible version of the full Cancer Immunotherapy Guideline is a quick-reference tool available in both digital and print.

Download SITC's Cancer Immunotherapy Guidelines Renal Cell Carcinoma Pocket Guide on any desktop or mobile device free today.*

*Available only through the Guideline Central App.

ORDER Digital/Print Guide

Cancer Immunotherapy Guidelines Renal Cell Carcinoma Subcommittee

Subcommittee Leadership

Michael B. Atkins, MD (co-chair)
Georgetown-Lombardi Comprehensive Cancer Center

Brian Rini, MD (co-chair)
Cleveland Clinic Taussig Cancer Institute

Subcommittee Members

Bill Bro Kidney Cancer Association	Ron Bukowski, MD Cleveland Clinic Taussig Cancer Institute	Bernard Faba Patient Perspectives
Jo Faba Patient Advocate	Robert A. Figlin, MD, FACP Cedars-Sinai Medical Center	Hans Hammers, MD, PhD Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Thomas Hutson, DO, PharmD Charles A. Sammons Cancer Center/Baylor Medical Center	Eric Jonasch, MD University of Texas MD Anderson Cancer Center	Richard W. Joseph, MD Mayo Clinic
Bradley C. Leibovich, MD, FACS Mayo Clinic	David F. McDermott, MD Beth Israel Deaconess Medical Center/Dana-Farber/Harvard Cancer Center	Tom Olencki, DO The Ohio State University Medical Center
Allan J. Pantuck, MD University of California, Los Angeles Institute of Urologic Oncology	David I. Quinn, MD, PhD, MBBS, FRACP University of Southern California Norris Comprehensive Cancer Center	Virginia Seery, MSN, RN, ANP-BC Beth Israel Deaconess Medical Center/Dana-Farber/Harvard Cancer Center
Martin Voss, MD – Memorial Sloan Kettering Cancer Center	Virginia Seery, MSN, RN, ANP-BC Beth Israel Deaconess Medical Center/Dana-Farber/Harvard Cancer Center	Martin Voss, MD – Memorial Sloan Kettering Cancer Center
Christopher G. Wood, MD University of Texas MD Anderson Cancer Center	Laura S. Wood, RN, MSN, OCN® Cleveland Clinic Taussig Cancer Institute